OCT 06, 2018 03:53 PM PDT

New Class of Drugs for Breast Cancer Therapy

WRITTEN BY: Nouran Amin

Image via Drug Target Review

Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively being created to degrade or inhibit estrogen receptors: the molecular protein which is believed to be, over the last 30 decades of research, the single most proven target in breast cancer therapy. The new class of molecules utilizes a unique biochemical mechanism that may stop or eradicate breast tumors, especially for patients with drug-resistant breast cancer or in the stages of dangerous metastasis. These developed molecules are better known as selective estrogen receptor degraders (SERDs).

“The unique benefit of our compounds is that this is a fundamentally different type of structure that was previously not known to degrade or inhibit estrogen receptors,” explains lead researcher Dr. Abhishek Sharma, “It’s not a tweak of an existing drug; it works in a completely different way.”

Due to the clinical needs and huge market potential, multiple pharmaceutical companies have invested heavily in developing SERDs. However, these companies were mainly unsuccessful in that particular drug development due to their approaches. More specifically, they focused on modifying the structure of SERDs that was originally developed decades ago.

"A schematic of a fundamentally new molecule can halt the proliferation and growth of breast cancer cells in the lab." Image Credit: Stevens Institute of Technology via Drug Target Review

The main issue facing breast cancer therapy is that many tumors no longer respond to the intended treatments, this is the essence of drug-resistance. When tumors have become drug-resistant, healthcare provides seek toxic chemotherapies to prevent cancer from relapsing and progressing. Additionally, previous SERDs are challenging to ‘package’ into pills, and large, painful injections directly into a patient’s muscles are required. Recently, clinical trial drugs have been pulled out of studies because of side effects.

Breast cancer currently affects one in eight U.S. women and tens of millions worldwide. Now, researchers are seeking ways to better combat breast cancer.

The researchers placed a core substance for estrogen receptors into a series of experimental side-chain compounds known as degrons. Once the substance has latched to the estrogen receptor, the degrons destroyed it by hijacking a cancer cell’s protein-disposal machinery and changing the direction to the receptor. However, the research team went as step further by synthesizing several variations of the novel compound which were then tested to see how they molecularly interacted with the cancer cells’ estrogen receptors. The new drugs were found to degrade the estrogen receptors and inhibit cell signaling that cue for cell growth. Additionally, they blocking the estrogen from binding and inhibited the growth and proliferation of breast cancer cells. “We consider these results to be very promising,” said Dr. Sharma. “This is a novel molecular structure, and several analogues produced excellent early activity.”

Source: Drug Target Review, ACS Medicinal Chemistry Letters

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
OCT 31, 2018
Cancer
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
NOV 25, 2018
Microbiology
NOV 25, 2018
Researchers Learn How Hantavirus Infects Cells
First identified in 1993, hantavirus infections can cause dangerous and potentially deadly respiratory infections....
DEC 09, 2018
Cannabis Sciences
DEC 09, 2018
Targeting CB1 Endocannabinoid Receptor: Specificity is the Key
The human endocannabinoid system (ECS) is one of the body's largest network of neurotransmitters, receptors, and neuromodulators. This system plays a r...
DEC 27, 2018
Microbiology
DEC 27, 2018
Reputed Medicinal Soil Yields a Superbug-killing Bacterium
It's no secret that antibiotic resistance is a problem that already poses a serious threat to public health, and it's expected to get worse....
JAN 07, 2019
Cell & Molecular Biology
JAN 07, 2019
Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer
Between 12 and 17% of all breast cancer cases are triple-negative, a highly aggressive type with few therapeutic options....
Loading Comments...